Nanoparticle-mediated drug delivery for treating melanoma

Vaibhav Mundra, Wei Li, Ram I. Mahato

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations


Melanoma originated from melanocytes is the most aggressive type of skin cancer with limited treatment options. New targeted therapeutic options with the discovery of BRAF and MEK inhibitors have shown significant survival benefits. Despite the recent progress, development of chemoresistance and systemic toxicity remains a challenge for treating metastatic melanoma. While the response from the first line of treatment against melanoma using dacarbazine remains only 5-10%, the prolonged use of targeted therapy against mutated oncogene BRAF develops chemoresistance. In this review, we will discuss the nanoparticle-based strategies for encapsulation and conjugation of drugs to the polymer for maximizing their tumor distribution through enhanced permeability and retention effect. We will also highlight photodynamic therapy and design of melanoma-targeted nanoparticles.

Original languageEnglish (US)
Pages (from-to)2613-2633
Number of pages21
Issue number16
StatePublished - Aug 1 2015


  • active targeting
  • metastatic melanoma
  • multidrug resistance
  • nanoparticles
  • photodynamic therapy
  • polymer-drug conjugate
  • tumor initiating cells

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • General Materials Science


Dive into the research topics of 'Nanoparticle-mediated drug delivery for treating melanoma'. Together they form a unique fingerprint.

Cite this